WASHINGTON, March 1 (Reuters) - OncoGenex Technologies Inc., a Canadian biopharmaceutical firm focused on new cancer therapies, on Thursday cut its planned initial public offering to $7.50 to $8.50 per share from a previous range of $10 to $12.
WASHINGTON, March 1 (Reuters) - OncoGenex Technologies Inc., a Canadian biopharmaceutical firm focused on new cancer therapies, on Thursday cut its planned initial public offering to $7.50 to $8.50 per share from a previous range of $10 to $12.
